Gene
SLC44A4
SLC44A4 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Actionable biomarkers (2), Trial mentions (24), Target-disease associations (60), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention SLC44A4. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 1 of 8,738 | 0.01% | not measured | |
| 2025 | 1 of 8,875 | 0.01% | not measured | |
| 2024 | 2 of 8,597 | 0.02% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 4 of 11,460 | 0.03% |
| 2022 | 1 of 8,285 | 0.01% | 6 of 13,598 | 0.04% |
| 2021 | 1 of 8,692 | 0.01% | 4 of 15,045 | 0.03% |
| 2020 | 2 of 7,640 | 0.03% | 5 of 14,459 | 0.03% |
| 2019 | 3 of 7,300 | 0.04% | 3 of 12,159 | 0.02% |
| 2018 | 4 of 6,927 | 0.06% | 2 of 11,854 | 0.02% |
| 2017 | 3 of 6,558 | 0.05% | 3 of 11,595 | 0.03% |
Showing 10 of 37 years.
Actionable biomarkers (2)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| SLC44A4 overexpression | Slc44a4 Inhibitors | response-associated | pancreatic adenocarcinoma | Cancer Genome Interpreter |
| SLC44A4 overexpression | Slc44a4 Inhibitors | response-associated | prostate adenocarcinoma | Cancer Genome Interpreter |
Trial mentions (24)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05316129 | Trial eligibility (AACT) |
| NCT04913571 | Trial eligibility (AACT) |
| NCT07387198 | Trial eligibility (AACT) |
| NCT03352531 | Trial eligibility (AACT) |
| NCT06193486 | Trial eligibility (AACT) |
Showing 5 of 24 trial mentions.
Target-disease associations (60)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Autosomal recessive early-onset inflammatory bowel disease | gastrointestinal disease | Mouse knockout (IMPC) |
| Barrett's esophagus | gastrointestinal disease | Expression Atlas |
| Crigler-Najjar syndrome type 2 | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| Crohn's disease | gastrointestinal disease | Mouse knockout (IMPC) |
| Glycogen storage disease due to hepatic glycogen synthase deficiency | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 60 associations.
Vendor sourcing (95)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Akeso | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : 1. Known nodular lymphoma predominant Hodgkin lymphoma or Grey zone lymphoma. 2. Lymphoma involving the central nervous system. 3. Participated in other c... | View trial NCT03722147 |
| Akeso | Trial sponsor | Mentioned in trial textTrial free-text mention | CTL4 | View trial NCT03722147 |
| Akesobio Australia Pty Ltd | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * History of severe hypersensitivity reactions to other mAbs. * For dose-escalation phase (Phase 1a), prior exposure to any anti-PD-1, anti-PD-L1, anti-CT... | View trial NCT03352531 |
| Akesobio Australia Pty Ltd | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | : * History of severe hypersensitivity reactions to other mAbs. * Prior exposure to any anti-PD-1, anti-PD-L1, anti-CTL4 antibody or any other antibody or d... | View trial NCT03261011 |
| Akesobio Australia Pty Ltd | Trial sponsor | Mentioned in trial textTrial free-text mention | CTL4 | View trial NCT03352531 |
Showing 5 of 95 sourcing records.
Trial-cited literature (31)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| The importance of thiamine (vitamin B1) in humans. | Bioscience reports | 2023 | 134 |
| Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. | Molecular cancer | 2023 | 111 |
| Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. | JHEP reports : innovation in hepatology | 2023 | 74 |
| Efficiency of occlusal splint therapy on orofacial muscle pain reduction: a systematic review. | BMC oral health | 2023 | 34 |
| Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022 | 163 |
Showing 5 of 31 papers.
Protein variant mentions (2)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.M687V | 1 | 2012 | PMID 22859988 |
| p.R333W | 1 | 2015 | PMID 25741868 |
Literature-extracted relations (1)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| IPILIMUMAB | Chemical | negative_correlate |
Melanoma Brain Metastases in the Era of Target Therapies: An Overview. | 2020 |
Organizations publishing (51)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 3 | 2012 to 2022 |
| Dana-Farber Cancer Institute | Other | 2 | 2022 |
| Harvard Medical School | Academic | 2 | 2016 to 2022 |
| Allegheny Health Network | Hospital | 1 | 2022 |
| Arizona's Public Universities | Government | 1 | 2022 |
Showing 5 of 51 organizations.
Where SLC44A4 appears
- biological_process
- cancer or benign tumor
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- nervous system disease
54 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, assay-provider ledger, and human sample screening reference.